Metin Kurtoglu sold $1.4M of RNAC
Chief Technology Officer at Cartesian Therapeutics, Inc.. 82,368 shares at an average of $17.46, traded Nov 14, 2024, filed Nov 18, 2024.
Score components
- +15RoleOfficer
- +25Trade size$1.4M at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -8.9%, 3m +5.9%, 6m -44.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001453687-24-000132, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 14, 2024 | MOption exercise Common Stock | +25,900 | $1.41 | $37k | 76,933 | Nov 18, 2024 |
| Nov 14, 2024 | SOpen-market sale Common Stock | -21,900 | $16.33 | $358k | 55,033 | Nov 18, 2024 |
| Nov 14, 2024 | SOpen-market sale Common Stock | -4,000 | $17.06 | $68k | 51,033 | Nov 18, 2024 |
| Nov 15, 2024 | MOption exercise Common Stock | +22,068 | $1.41 | $31k | 73,101 | Nov 18, 2024 |
| Nov 15, 2024 | SOpen-market sale Common Stock | -22,068 | $17.20 | $379k | 51,033 | Nov 18, 2024 |
| Nov 18, 2024 | MOption exercise Common Stock | +34,400 | $1.41 | $49k | 85,433 | Nov 18, 2024 |
| Nov 18, 2024 | SOpen-market sale Common Stock | -16,672 | $18.19 | $303k | 68,761 | Nov 18, 2024 |
| Nov 18, 2024 | SOpen-market sale Common Stock | -17,728 | $18.58 | $329k | 51,033 | Nov 18, 2024 |
| Nov 14, 2024 | MOption exercise Stock Option (Right to Buy)derivative | -25,900 | - | - | 187,920 | Nov 18, 2024 |
| Nov 15, 2024 | MOption exercise Stock Option (Right to Buy)derivative | -22,068 | - | - | 165,852 | Nov 18, 2024 |
| Nov 18, 2024 | MOption exercise Stock Option (Right to Buy)derivative | -34,400 | - | - | 131,452 | Nov 18, 2024 |
Related signals
Other insiders at Cartesian Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 53Moderate | RNACbuy Cartesian Therapeutics, Inc. | Timothy A Springer director, owner | $1.5M 149,075 shares | +2% | |
| 45Moderate | RNACbuy Cartesian Therapeutics, Inc. | Timothy A Springer director, owner | $1.4M 89,863 shares | +1% | |
| 30Weak | RNACbuy Cartesian Therapeutics, Inc. | Timothy A Springer director, owner | $366k 20,967 shares | +0% | |
| 54Moderate | Cartesian Therapeutics, Inc. | Carsten Brunn President and CEO | $290k 17,271 shares | -8% | |
| 48Moderate | Cartesian Therapeutics, Inc. | Blaine Davis Chief Financial Officer | $134k 7,989 shares | -8% | |
| 40Moderate | Cartesian Therapeutics, Inc. | Emily English Chief Operations Officer | $30k 1,797 shares | -4% | |
| 36Weak | Cartesian Therapeutics, Inc. | Christopher M Jewell Chief Scientific Officer | $43k 2,550 shares | -5% | |
| 35Weak | Cartesian Therapeutics, Inc. | Milos Miljkovic Chief Medical Officer | $32k 1,880 shares | -5% | |
| 39Weak | Cartesian Therapeutics, Inc. | Metin Kurtoglu Chief Technology Officer | $82k 4,875 shares | -7% | |
| 40Moderate | RNACbuy Cartesian Therapeutics, Inc. | Timothy A Springer director, owner | $965k 52,189 shares | +1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.